A Phase II Trial Investigating Vemurafenib for the Treatment of Hairy Cell Leukemia
Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.
Clinical Pearls
Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.
- This phase II trial has 13 patients enrolled and is still accruing
- Patients in the trial will receive the same dose of vemurafenib that is approved for the treatment of late-stage melanoma
- Following three cycles of therapy, disease response is assessed, and patients can continue on vemurafenib for three additional cycles
Recent Videos
Related Content
